273 related articles for article (PubMed ID: 10833410)
1. The importance of adenosine deaminase for lymphocyte development and function.
Aldrich MB; Blackburn MR; Kellems RE
Biochem Biophys Res Commun; 2000 Jun; 272(2):311-5. PubMed ID: 10833410
[TBL] [Abstract][Full Text] [Related]
2. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation.
Blackburn MR; Kellems RE
Adv Immunol; 2005; 86():1-41. PubMed ID: 15705418
[TBL] [Abstract][Full Text] [Related]
3. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities.
Blackburn MR; Aldrich M; Volmer JB; Chen W; Zhong H; Kelly S; Hershfield MS; Datta SK; Kellems RE
J Biol Chem; 2000 Oct; 275(41):32114-21. PubMed ID: 10908569
[TBL] [Abstract][Full Text] [Related]
4. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency.
Hershfield MS
Eur J Immunol; 2005 Jan; 35(1):25-30. PubMed ID: 15580654
[TBL] [Abstract][Full Text] [Related]
5. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
6. Function of murine adenosine deaminase in the gastrointestinal tract.
Xu PA; Kellems RE
Biochem Biophys Res Commun; 2000 Mar; 269(3):749-57. PubMed ID: 10720488
[TBL] [Abstract][Full Text] [Related]
7. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
8. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Ramsey WJ; Mullen CA; Blaese RM
Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
10. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency.
Blackburn MR; Datta SK; Kellems RE
J Biol Chem; 1998 Feb; 273(9):5093-100. PubMed ID: 9478961
[TBL] [Abstract][Full Text] [Related]
11. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.
Bax BE; Bain MD; Fairbanks LD; Webster AD; Ind PW; Hershfield MS; Chalmers RA
Eur J Haematol; 2007 Oct; 79(4):338-48. PubMed ID: 17680812
[TBL] [Abstract][Full Text] [Related]
12. [Severe combined immunodeficiencies: a case of adenosine-deaminase deficit].
Macellaro P; Savarino A; Cucchi G; Lazzati A; Zuccotti GV
Pediatr Med Chir; 2004; 26(3):191-5. PubMed ID: 16366403
[TBL] [Abstract][Full Text] [Related]
13. Adenosine deaminase-deficient mice: models for the study of lymphocyte development and adenosine signaling.
Aldrich MB; Blackburn MR; Datta SK; Kellems RE
Adv Exp Med Biol; 2000; 486():57-63. PubMed ID: 11783528
[No Abstract] [Full Text] [Related]
14. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
15. Severe combined immunodeficiency of reduced severity due to homozygosity for an adenosine deaminase missense mutation (Arg253Pro).
Hirschhorn R; Yang DR; Insel RA; Ballow M
Cell Immunol; 1993 Dec; 152(2):383-93. PubMed ID: 8258146
[TBL] [Abstract][Full Text] [Related]
16. [Deficiency of adenosine desaminase (ADA): clinical, biochemical, molecular and treatment aspects].
Tintos-Hernández JA; Dávalos-Rodríguez IP
Rev Invest Clin; 2011; 63(1):75-83. PubMed ID: 21585012
[TBL] [Abstract][Full Text] [Related]
17. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.
Apasov SG; Blackburn MR; Kellems RE; Smith PT; Sitkovsky MV
J Clin Invest; 2001 Jul; 108(1):131-41. PubMed ID: 11435465
[TBL] [Abstract][Full Text] [Related]
18. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of adenosine deaminase deficiency.
Markert ML
Immunodeficiency; 1994; 5(2):141-57. PubMed ID: 8032366
[TBL] [Abstract][Full Text] [Related]
20. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
